Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 11Active not recruiting 3Completed 2Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2

Interventions

Cyclophosphamide 956Radiotherapy 847Cisplatin 757Gemcitabine 657Carboplatin 603Docetaxel 598Paclitaxel 585Bevacizumab 580Fluorouracil 504Oxaliplatin 458Rituximab 453Surveys and Questionnaires 449Capecitabine 440Dexamethasone 428Doxorubicin 424Etoposide 411Irinotecan 389Cytarabine 376Filgrastim 369pembrolizumab 330Leucovorin 305Nivolumab 296fludarabine phosphate 294Melphalan 288Magnetic Resonance Spectroscopy 281Peripheral Blood Stem Cell Transplantation 279Blood Specimen Collection 279Methotrexate 276Lenalidomide 276Cetuximab 270

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × OTHER × defactinib × Clear all
NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02546531 2021-07-20

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

Phase 1 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡